Skip to main content

Evolve Healthcare Marketing

Marketing Transcranial Magnetic Stimulation (TMS) therapy poses challenges that many other behavioral health marketing efforts never have to worry about: almost any claim about the treatment carries regulatory implications. Most guides written for TMS practices chase lead volume and treat compliance as an afterthought, leaving practice owners to discover the rules after an ad gets rejected.

Check out our guide for practice owners and clinicians who want specialized behavioral health marketing that withstands modern-day regulatory scrutiny.

Why TMS Therapy Marketing Needs a Compliance-First Approach

What many marketers fail to connect is that TMS marketing claims sit under multiple regulators at the same time. The FDA oversees device benefit-risk claims and the FTC governs testimonials and results claims, while HHS’s Office for Civil Rights enforces HIPAA whenever patient stories are used.

General healthcare marketing playbooks don’t account for this overlap, which is where most TMS marketing campaigns run into trouble. That exposure is growing as more potential patients and referral sources encounter your practice through AI-generated search results rather than a standard results page, making showing up in AI-generated search results just as important as ranking traditionally and just as dependent on getting compliance right.

Marketing the Benefits of TMS Therapy Without Overstating Results

TMS therapy’s substantiated benefits start with FDA clearance for major depressive disorder in patients who haven’t responded to medication. It is also a non-invasive outpatient procedure without the usual side effects associated with antidepressants. Any benefit claim beyond what has been clinically proven matters for compliance. “FDA-cleared” is not the same as “FDA-approved”, and mixing the two up is one of the more common issues that usually end up getting flagged.

Green flag: “FDA-cleared for treatment-resistant depression.”

Red flag: “Guaranteed relief” or “Cures depression.”

Green flag: “Many patients report improved symptoms within weeks.”

Red flag: “Results in days” without proof.

How to Advertise TMS Therapy Success Rates Compliantly

Clinical literature cites ~50-60% response rates and ~30-35% full remission rates for TMS in treatment-resistant depression. These stats are great to use, but only if they’re disclosed the way the FTC requires. If your ad shows a result, it needs to be the kind of result that most people can realistically expect. If it isn’t, you have to clearly spell out what typical results usually look like. Just tacking on a disclaimer like “results not typical” isn’t enough on its own.

Source:

FTC Health Products Compliance Guidance | NIMH Major Depression Statistics

Disclosing TMS Therapy Side Effects in Marketing Materials

To stay on the good side of the FDA’s “fair balance” requirements, practices need to highlight benefits while clearly disclosing side effects, not just hiding them in a footnote.

Your checklist should include warnings like:

  • Scalp discomfort or headache during treatment (common)
  • Muscle twitching or tingling near treatment site
  • Lightheadedness
  • Rare risk of seizure

It is important to remember that these are just examples of disclosure, purely for marketing purposes. Clinical risk communication with individual patients still needs to be handled by your care team. For example, something like “Side effects may include scalp discomfort and headache; rare seizure risk” implements the fair balance the FDA is looking for compared to trying to hide the negatives on a linked disclaimer page.

Source:

FDA rTMS Systems Class II Special Controls Guidance

TMS vs. Other Treatments: Positioning Comparisons the Right Way

Comparison content ranks well and builds trust. However, this is only if it doesn’t imply ranking you can’t back up with proven studies and facts.

Treatment Invasiveness Typical Course FDA Status

Transcranial Magnetic Stimulation

Non-invasive

~3-6 weeks, daily sessions

FDA-cleared

Medication

Non-invasive
Ongoing

FDA-approved (depending on the drug)

Esketamine (SPRAVATO)

Non-invasive (nasal)
Twice-weekly induction, then maintenance

FDA-approved

Electroconvulsive therapy (ECT)

Invasive (requires anesthesia)
Series of sessions

FDA-approved

Don’t rank these; instead, frame them as different approaches for different clinical pictures. Implying that one treatment is better than another without head-to-head evidence is the kind of comparative claim that draws regulatory scrutiny.

Patient Testimonials and HIPAA: What TMS Practices Can (and Can’t) Do

Patient testimonials are your strongest marketing asset and your biggest HIPAA pain point. Using a patient’s likeness/story in marketing requires explicit written authorization, separate from the regular type of treatment consent. Evolve builds this kind of authorization confirmation into onboarding for every TMS client. Match your process to our helpful HIPAA-compliant marketing checklist before any testimonials go live.

Platform Ad Rules: Google and Meta Restrictions for TMS Practices

On top of federal rules, Google and Meta have their own healthcare ad policies, and practices that offer TMS are often caught off guard by these policies and the penalties for breaking them. Google requires healthcare advertisers to get certified (similar to LegitScript) and limits what you are able to claim about psychiatric devices; see Google’s restrictions on psychiatric device advertising to see what’s changed recently. Meta has further cracked down on healthcare advertising, as covered in Meta’s 2026 healthcare ad restrictions. These are exactly the kinds of changes an agency running TMS ad accounts spots before an ad gets flagged or shut down.

FAQ

1.   Can TMS practices legally advertise success rates?

Yes, TMS practices are able to legally advertise success rates but per FTC guidance, advertisers must also make sure that the claims are truthful and backed by clinical data.

2.   Does TMS therapy marketing require HIPAA authorization for patient testimonials?

Yes, using a patient’s story or image in marketing requires specific written authorization under 45 CFR 164.508.

3.   What happens if a TMS ad makes an unsubstantiated claim?

It risks platform disapproval, FTC enforcement action, or both, depending on the claim and how it is disclosed.

4.   Can I compare TMS to medication or SPRAVATO in ads?

Yes, but you can’t imply that it is better without head-to-head evidence to back it up.

5.   Does Google allow TMS therapy advertising?

Yes, within its healthcare ad policies. These may require certification and restrict certain device claims.

6.   What happens if I don’t disclose TMS side effects in an ad?

It can violate the FDA’s fair balance requirement and increase platform and regulatory risk.

Get Compliance-First TMS Marketing Support

Marketing TMS therapy well means balancing growth with regulatory risk, and that balance is easier to find with a partner that exclusively works in healthcare. Evolve Healthcare Marketing builds every campaign around this kind of compliance from the very start, so practices don’t have to piece together the rules and face the restrictions on their own.

If you want B2B marketing strategies for healthcare, backed by industry-leading experience from day one, talk to our team.

Search

Featured

What Kind of Medical Marketing Agency is Best for Your Practice? 

In this article, we explore the essential factors to consider when choosing a marketing partner, as well as the different types of agencies.

Recent Posts

Social Media

Leave a Reply

Your email address will not be published. Required fields are marked *